Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CT3001 |
| Synonyms | |
| Therapy Description |
CT3001 inhibits GPR35, which potentially leads to decreased YAP/TAZ signaling, enhanced antitumor immune response, and reduced tumor cell proliferation (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CT3001 | CT-3001|CT 3001 | CT3001 inhibits GPR35, which potentially leads to decreased YAP/TAZ signaling, enhanced antitumor immune response, and reduced tumor cell proliferation (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06598007 | Phase Ib/II | CT3001 | A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors | Recruiting | USA | 0 |